Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

BACKGROUND: LDL cholesterol (LDL-C) is a well established risk factor for cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds LDL receptors, targeting them for degradation. We therefore assessed the efficacy, safety, and tolerability of AMG 145, a human monoclonal IgG...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet
Autori principali: Giugliano, Robert P, Desai, Nihar R, Kohli, Payal, Rogers, William J, Somaratne, Ransi, Huang, Fannie, Liu, Thomas, Mohanavelu, Satishkumar, Hoffman, Elaine B, McDonald, Shannon T, Abrahamsen, Timothy E, Wasserman, Scott M, Scott, Robert, Sabatine, Marc S
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4347805/
https://ncbi.nlm.nih.gov/pubmed/23141813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(12)61770-X
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi